KYMR
Kymera Therapeutics, Inc. · Healthcare · Biotechnology
动量输入（同类管理人）：
持有人广度 +9.1% ·
股份流向 +5.7% ·
净新建仓位 +8.3%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q4 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 6.99K | $515,619 | +1 | n/a |
| Q2 2026 | 102 | +13 | 52.73M | $6.01B | +15 | −1 |
| Q1 2026 | 91 | -4 | 48.20M | $4.01B | +6 | −11 |
| Q4 2025 | 94 | 0 | 48.74M | $3.79B | +1 | n/a |
| Q3 2025 | 17 | 0 | 32.08M | $1.82B | n/a | −1 |
| Q2 2025 | 15 | +3 | 31.72M | $1.38B | +3 | n/a |
| Q1 2025 | 9 | -3 | 16.51M | $451.78M | n/a | −3 |
| Q4 2024 | 12 | +1 | 15.63M | $628.72M | +1 | n/a |
| Q3 2024 | 10 | 0 | 13.10M | $619.83M | +1 | −1 |
| Q2 2024 | 10 | n/a | 13.21M | $394.27M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.87M | +3.4% | $276.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 5.31M | +14.9% | $213.51M | 0.0% | ▲ Add | 3 | SEC ↗ ×7 |
| 3 | State Street Global Advisors ✦ (被动) | 1.69M | n/a | $67.94M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 1.11M | +5.0% | $44.48M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 173.75K | -35.7% | $6.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Soros Fund Management ✦ | 120.37K | 新增 | $4.84M | 0.1% | New | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 115.92K | +205.0% | $4.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Norges Bank ✦ (被动) | 91.23K | 0.0% | $3.67M | 0.0% | Held | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 82.58K | -56.1% | $3.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 58.57K | -4.5% | $2.36M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 11 | Marshall Wace ✦ | 6.83K | -94.2% | $274,972 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 6.58K | -46.4% | $264,552 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Soros Fund Management | $4.84M | 0.1% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 254 持有人, 96.17M 股份, $7.04B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director · 262 股 · $30,423
Officer, Director · 4.88K 股 · $552,158
Officer, Director · 7.60K 股 · $869,782
Officer, Director · 8.23K 股 · $949,742
Officer, Director · 3.52K 股 · $392,826
Officer, Director · 5.51K 股 · $618,985
Officer · 3.02K 股 · $353,350
Officer · 2.14K 股 · $251,247
Officer · 1.21K 股 · $139,700
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
3.3% 占股份类别 · 查看 SEC 原始申报文件 ↗